AB Corporate Bond ETF

Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.

EYEG is an actively managed fund that invests in USD-denominated, investment grade corporate bonds of any maturity or duration.

WALTHAM, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system, today announced that it has entered into a securities purchase agreement in connection with a private placement (the “Private Placement”) with an affiliate of Armistice Capital, LLC (“Armistice”) for aggregate gross proceeds of approximately $8.0 million. The Private Placement is expected to close on or about January 6, 2021, subject to the satisfaction of customary closing conditions.

EyeGate Enters Into Agreement for $8.0 Million Private Placement

EyeGate Pharma shares doubled on Monday morning following the news of its acquisition of Austria's Panoptes Pharma. Zacks earlier boosted its target on EYEG stock to $15 a share.

EYEG Stock: Why EyeGate Pharma Is Up More Than 80% Today

Expands Pipeline Beyond Ophthalmology with PP-001 , a Clinical Stage, Best-in-Class DHODH Inhibitor

EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma

Investors Should Be Excited For EyeGate's Ocular Bandage

Eyegate: Speculative Buy For Their Better-Than-SOC Treatment In Corneal Wound Repair

Shares of EyeGate Pharmaceuticals Inc. rallied 95% in premarket trading on the news that the company's experimental eye-drop bandage performed better than the standard of care, which is a bandage contact lens, in patients in need of corneal wound repair.

EyeGate shares jump on data for eye treatment data

Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG) shares are trading higher after the company received FDA approval to initiate its follow-on pilot study for punctate epitheliopathies (PE).

News for AB Corporate Bond ETF ETF (EYEG)